当前位置:首页 - 行情中心 - 赛托生物(300583) - 财务分析 - 利润表

赛托生物

(300583)

  

流通市值:22.34亿  总市值:22.76亿
流通股本:1.86亿   总股本:1.90亿

利润表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、营业总收入612,731,527.67328,046,378.971,016,869,821.22749,188,335.44
  营业收入612,731,527.67328,046,378.971,016,869,821.22749,188,335.44
二、营业总成本572,849,329.95320,008,510.911,055,969,458.02796,360,986.67
  营业成本456,903,868.72255,612,893.46864,319,954.46655,327,098.98
  税金及附加9,063,440.535,049,692.5312,233,610.279,222,608.44
  销售费用8,387,883.796,430,014.711,036,043.429,462,575.93
  管理费用59,994,936.4633,048,216.5294,722,377.0666,563,051.46
  研发费用21,500,162.7410,112,695.241,543,067.1432,249,551.03
  财务费用16,999,037.719,754,998.532,114,405.6723,536,100.83
  其中:利息费用14,223,102.757,362,248.1129,027,615.5421,777,304.76
  其中:利息收入588,890.67385,184.272,102,033.291,593,634.73
三、其他经营收益
  加:投资收益3,287,943.262,491,107.26,246,926.135,391,355.27
  资产处置收益217,907.39217,907.39-824,300.99-165,020.44
  资产减值损失(新)-4,754,913.23-3,957,852.94-47,032,700.65-30,954,604.75
  信用减值损失(新)-1,632,370.12-3,411,569-6,041,112.37-9,637,137.21
  其他收益3,644,851.992,079,342.6510,486,032.638,399,896.25
四、营业利润40,645,617.015,456,803.36-76,264,792.05-74,138,162.11
  加:营业外收入1.041,054,261.7834,365.6510,613.64
  减:营业外支出87,816.9748,283.18834,043.791,073,659.07
五、利润总额40,557,801.086,462,781.96-77,064,470.19-75,201,207.54
  减:所得税费用9,598,800.511,886,947.657,616,344.253,927,317.08
六、净利润30,959,000.574,575,834.31-84,680,814.44-79,128,524.62
(一)按经营持续性分类
  持续经营净利润30,959,000.574,575,834.31-84,680,814.44-79,128,524.62
(二)按所有权归属分类
  归属于母公司股东的净利润30,227,358.263,616,573.14-73,147,490.03-69,230,279.84
  少数股东损益731,642.31959,261.17-11,533,324.41-9,898,244.78
  扣除非经常损益后的净利润29,278,388.881,708,880.23-76,650,429-72,387,914.43
七、每股收益
  (一)基本每股收益0.160.02-0.39-0.36
  (二)稀释每股收益0.160.02-0.39-0.36
九、综合收益总额30,959,000.574,575,834.31-84,680,814.44-79,128,524.62
  归属于母公司股东的综合收益总额30,227,358.263,616,573.14-73,147,490.03-69,230,279.84
  归属于少数股东的综合收益总额731,642.31959,261.17-11,533,324.41-9,898,244.78
公告日期2026-08-292026-04-282026-04-282025-10-29
审计意见(境内)标准无保留意见
TOP↑